Dashboard
Manage Tickers

OGNOrganon & Co.

NYSE organon.com


$ 20.54 $ -0.33 (-1.58 %)    

Tuesday, 17-Sep-2024 15:59:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.83 $ 0.25 (0.05 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.14 $ 0.23 (0.04 %)
TLT $ 100.82 $ -0.49 (-0.48 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ 20.55
$ 20.90
$ 20.55 x 200
-- x --
$ 20.39 - $ 20.94
$ 10.38 - $ 23.10
1,345,785
na
5.29B
$ 0.81
$ 5.29
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-03-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-03-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-05-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-04-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-06-2022 03-31-2022 10-Q
11 03-21-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 06-21-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-signs-of-stability
JP Morgan Shows Most Interest In Teva, Org...
09/06/2024 17:46:07

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva,...

jp-morgan-downgrades-organon-to-underweight-raises-price-target-to-20
JP Morgan Downgrades Organon to Underweigh...
09/06/2024 12:18:03

JP Morgan analyst Chris Schott downgrades Organon (NYSE:OGN) from Neutral to Underweight and raises the price target from $1...

Core News & Articles
Organon Has Expanded Its Agreement With El...
08/20/2024 11:34:35

Core News & Articles
CNBC Halftime Report Final Trades: Uber Te...
08/06/2024 17:00:33

correction-organon--co-revises-fy24-revenue-guidance-from-62b-65b-to-625-645b-vs-6407b-est
CORRECTION: Organon & Co. Revises FY24 Rev...
08/06/2024 16:28:58

Full year 2024 financial guidance is presented below on a non-GAAP basis, except revenue.Previous guidance as of May 2, 2024Cur...

organon-q2-2024-adj-eps-112-beats-108-estimate-sales-1607b-miss-1631b-estimate
Organon Q2 2024 Adj. EPS $1.12 Beats $1.08...
08/06/2024 11:31:28

jim-cramer-says-no-to-this-health-care-stock-recommends-holding-on-to-constellation-energy-its-up-a-huge-amount
Jim Cramer Says No To This Health Care Sto...
07/30/2024 12:48:05

Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot o...

organon-says-european-medicines-agency-ema-validates-henlius-and-organon-filings-for-prolia-and-xgeva-denosumab-biosimilar-candidate-hlx14
Organon Says European Medicines Agency (Em...
05/24/2024 10:03:07

Company announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HL...

wall-streets-most-accurate-analysts-views-on-3-health-care-stocks-with-over-5-dividend-yields
Wall Street's Most Accurate Analysts' View...
05/10/2024 12:01:24

reported-earlier-organon-prices-1b-dual-series-senior-notes-500m-6750-secured-500m-7875-unsecured-both-due-2034
Reported Earlier, Organon Prices $1B Dual ...
05/08/2024 08:02:01

The Companies intend to use the net proceeds from the sale of the Notes to repay a portion of their borrowings under the Credit...

organon-announces-proposed-10b-senior-notes-offering
Organon Announces Proposed $1.0B Senior No...
05/07/2024 11:59:49

Organon (NYSE:OGN) ("Organon"), a global healthcare company with a focus on women's health, announced today that it...

goldman-sachs-maintains-neutral-on-organon-raises-price-target-to-20
Goldman Sachs Maintains Neutral on Organon...
05/06/2024 15:27:04

Goldman Sachs analyst Chris Shibutani maintains Organon (NYSE:OGN) with a Neutral and raises the price target from $18 to $20.

goldman-sachs-maintains-neutral-on-organon-raises-price-target-to-20
Goldman Sachs Maintains Neutral on Organon...
05/03/2024 15:59:13

Goldman Sachs analyst Chris Shibutani maintains Organon (NYSE:OGN) with a Neutral and raises the price target from $18 to $20.

organon-beats-on-q1-womens-health-leads-the-charge
Organon Beats On Q1, Women's Health Leads ...
05/02/2024 17:58:23

Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.

organon-reaffirms-2024-revenues-guidance-of-62b-65b-versus-consensus-of-637b
Organon Reaffirms 2024 Revenues Guidance O...
05/02/2024 11:34:39

organon-q1-2024-adj-eps-122-beats-093-estimate-sales-1622b-beat-1563b-estimate
Organon Q1 2024 Adj EPS $1.22 Beats $0.93 ...
05/02/2024 11:32:43

Organon (NYSE:OGN) reported quarterly earnings of $1.22 per share which beat the analyst consensus estimate of $0.93 by 31.18 p...

piper-sandler-maintains-overweight-on-organon-raises-price-target-to-24
Piper Sandler Maintains Overweight on Orga...
04/29/2024 11:44:11

Piper Sandler analyst David Amsellem maintains Organon (NYSE:OGN) with a Overweight and raises the price target from $22 to ...

wall-streets-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields
Wall Street's Most Accurate Analysts' View...
03/13/2024 12:24:39

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often com...

5-value-stocks-in-the-healthcare-sector
5 Value Stocks In The Healthcare Sector
03/04/2024 14:44:45

new-york-attorney-general-urges-fda-action-on-widely-used-asthma-drugs-concerns-over-pediatric-safety
New York Attorney General Urges FDA Action...
02/26/2024 15:56:30

The Attorney General of New York, Letitia James, has called on the FDA to address safety risks associated with the widely used ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION